Striving to revolutionize mental health research
World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry
Search
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Sophia Malki: A Woman on the Rise
Sophia Malki: A Woman on the Rise
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
The Urgency for Heart Failure Research and New Treatment Options
The Urgency for Heart Failure Research and New Treatment Options
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
new_health_insurance_marketplace_coverage_options_and_your_health_coverage.pdf
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Boehringer Cares Patient Assistance Portal
Click here to find out more about Boehringer Ingelheim's Boehringer Cares patient assistance program portal.
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Borderline Personality Disorder
Borderline Personality Disorder
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US
BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.
Biologic Medicines & Biosimilars PDF
Medicine & Regulatory Video
Taimi Sahlin, a therapeutic specialist with Boehringer Ingelheim Canada describes her career as challenging and motivating.
Six creative Connecticut students turn aspiring ideas into inventive innovation
Learn about the 2023 Connecticut Invention Convention winners.